Bodor ET[au] - Search Results

Year	Number of Results
2003	3
2004	2
2005	1
2007	1
2008	2
2012	1
2016	1
2022	0

1

Nicotinic acid: an old drug with a promising future.

Bodor ET, Offermanns S. Bodor ET, et al. Br J Pharmacol. 2008 Mar;153 Suppl 1(Suppl 1):S68-75. doi: 10.1038/sj.bjp.0707528. Epub 2007 Nov 26. Br J Pharmacol. 2008. PMID: 18037924 Free PMC article. Review.

2

Nicotinic acid: pharmacological effects and mechanisms of action.

Gille A, Bodor ET, Ahmed K, Offermanns S. Gille A, et al. Among authors: bodor et. Annu Rev Pharmacol Toxicol. 2008;48:79-106. doi: 10.1146/annurev.pharmtox.48.113006.094746. Annu Rev Pharmacol Toxicol. 2008. PMID: 17705685 Review.

3

Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin.

Bodor ET, Wu WM, Chandran VR, Bodor N. Bodor ET, et al. J Pharm Sci. 2016 Sep;105(9):2873-2878. doi: 10.1016/j.xphs.2016.03.028. Epub 2016 May 11. J Pharm Sci. 2016. PMID: 27179671

4

Structure of Galpha(i1) bound to a GDP-selective peptide provides insight into guanine nucleotide exchange.

Johnston CA, Willard FS, Jezyk MR, Fredericks Z, Bodor ET, Jones MB, Blaesius R, Watts VJ, Harden TK, Sondek J, Ramer JK, Siderovski DP. Johnston CA, et al. Among authors: bodor et. Structure. 2005 Jul;13(7):1069-80. doi: 10.1016/j.str.2005.04.007. Structure. 2005. PMID: 16004878 Free PMC article.

5

Purification and functional reconstitution of the human P2Y12 receptor.

Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK. Bodor ET, et al. Mol Pharmacol. 2003 Nov;64(5):1210-6. doi: 10.1124/mol.64.5.1210. Mol Pharmacol. 2003. PMID: 14573771

6

RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of Gi family G-proteins with differential selectivity and maximal activity.

Hooks SB, Waldo GL, Corbitt J, Bodor ET, Krumins AM, Harden TK. Hooks SB, et al. Among authors: bodor et. J Biol Chem. 2003 Mar 21;278(12):10087-93. doi: 10.1074/jbc.M211382200. Epub 2003 Jan 16. J Biol Chem. 2003. PMID: 12531899 Free article.

7

The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.

Wu WM, Bodor ET, Howes J, Bodor N. Wu WM, et al. Among authors: bodor et. Pharmazie. 2012 May;67(5):406-10. Pharmazie. 2012. PMID: 22764572

8

C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists.

Kim MG, Bodor ET, Wang C, Harden TK, Kohn H. Kim MG, et al. Among authors: bodor et. J Med Chem. 2003 May 22;46(11):2216-26. doi: 10.1021/jm020572p. J Med Chem. 2003. PMID: 12747793

9

C(8)-substituted 1-azabicyclo[3.3.1]non-3-enes: a novel scaffold for muscarinic receptor ligands.

Kim MG, Bodor ET, Harden TK, Kohn H. Kim MG, et al. Among authors: bodor et. Bioorg Med Chem. 2004 May 1;12(9):2357-67. doi: 10.1016/j.bmc.2004.02.016. Bioorg Med Chem. 2004. PMID: 15080933

10

Delineation of ligand binding and receptor signaling activities of purified P2Y receptors reconstituted with heterotrimeric G proteins.

Bodor ET, Waldo GL, Blaesius R, Harden TK. Bodor ET, et al. Purinergic Signal. 2004 Dec;1(1):43-9. doi: 10.1007/s11302-004-4748-1. Purinergic Signal. 2004. PMID: 18404399 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results